Table 2

TrueBlue outcomes at 6 months in the intervention and control groups

InterventionControlBetween groups
nBaseline6 monthsWithin group*nBaseline6 monthsWithin group†
PHQ9 depression score16410.7±0.87.1±0.8p<0.00114611.6±0.99.0±0.9p<0.001p=0.012
SF36v2 mental-health score‡7137.2±3.441.1±3.4p=0.034Not recordedNS
SF36v2 physical-health score‡7139.9±2.242.5±2.6p=0.023Not recordedNS
Body mass index (kg/m2)16231.3±1.031.2±1.0NS10330.8±1.231.0±1.0NSNS
Waist (cm)161104.7±2.4105.0±2.4NS80104.2±4.0105.8±3.2NSNS
Systolic blood pressure (mm Hg)161134.2±3.0132.4±2.8NS112133.5±3.8131.2±3.4NSNS
Total cholesterol (mmol/l)1584.21±0.164.22±0.14NS1094.41±0.204.44±0.20NSNS
LDL (mmol/l)1542.23±0.122.17±0.14NS862.37±0.182.29±0.20NSNS
HDL (mmol/l)1541.23±0.061.29±0.06p=0.023931.17±0.061.27±0.08p=0.011NS
Triglycerides (mmol/l)1581.72±0.141.66±0.12NS1041.84±0.221.75±0.18NSNS
HbA1c (%)§896.97±0.246.90±0.26NS677.22±0.347.40±0.36NSp=0.049
10- Year CVD risk¶6126.9±3.226.1±3.2NS4626.3±3.624.7±3.2NSNS
Smoking16215 (9%)13 (8%)NS11013 (12%)13 (12%)NSNS
Alcohol10447 (45%)51 (49%)NS4227 (64%)27 (64%)NSNS
Exercises 30 min/day, 5 days/week16266 (41%)97 (60%)p<0.0017522 (29%)22 (29%)NSp<0.001
Referred to exercise programme16232 (20%)58 (36%)p<0.00111115 (14%)10 (9%)NSp<0.001
Attends exercise programme16212 (7%)23 (14%)p=0.0417912 (15%)9 (11%)NSNS
On antidepressant medication16227 (17%)34 (21%)NS11331 (27%)36 (32%)NSp=0.025
Referred to mental health worker16247 (29%)58 (36%)p=0.02211410 (9%)24 (21%)p<0.001p<0.001
Attends mental health worker16210 (6%)37 (23%)p<0.00110914 (13%)11 (10%)NSp=0.044
  • The 95% confidence ranges are indicated by the±sign. Note that lower scores indicate improvement for all items except the SF36v2 and HDL results, where higher scores indicate improvement.

  • Unit of alcohol is 10 g of ethanol.

  • The values in brackets are the percentages of the total n.

  • *Significant difference between baseline and 6-month values within the intervention clinics.

  • †Significant difference between baseline and 6 months within the control clinics.

  • ‡SF36v2 questionnaires were not collected by all clinics.

  • §HbA1c results were only available for patients with T2DM.

  • ¶CVD risk could only be calculated for patients with T2DM only.

  • CVD, cardiovascular disease; HbA1c, glycosylated haemoglobin was measured only for patients with diabetes; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, no significant difference; PHQ9, nine-question Patient Health Questionnaire; SF36v2, V.2 of the Short Form 36-Question health survey; T2DM, type 2 diabetes.